Potential Impact of Amantadine on Aggression in Chronic Traumatic Brain Injury by Hammond, Flora M. et al.
Amantadine for TBI Aggression & Anger 
Title: 
Potential Impact of Amantadine on Aggression in Chronic Traumatic Brain Injury 
Flora M. Hammond; James F. Malec; Ross D. Zafonte; Mark Sherer; Jennifer 
Bogner; Sureyya Dikmen; Marybeth P. Whitney; Kathleen R. Bell; Susan M. Perkins; 
Elizabeth A. Moser 
ABSTRACT: 
Objective: To assess the effects of amantadine on anger and aggression among 
individuals with a chronic traumatic brain injury (TBI). 
Methods: A cohort of 118 persons with chronic TBI (> 6 months post-injury) and 
moderate-severe aggression selected from a larger cohort of 168 participants enrolled in a 
parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100 mg 
twice daily (n=82) vs placebo (n=86) for treatment of irritability were studied. Anger and 
aggression were measured at treatment days 0, 28 and 60 using observer-rated and 
participant-rated State Trait Anger Expression Inventory-2 (STAXI-2) and 
Neuropsychiatric Inventory Agitation/Aggression Domain (NPI-A) Most Problematic 
and Distress scores.  
Results: Participant-rated Day-60 NPI-A Most Problematic (adjusted p = 0.0118) and 
NPI-A Distress (adjusted p = 0.0118) were statistically significant between the two 
groups, but STAXI-2 differences were not significant after adjustment for multiple 
comparisons.  Substantial improvements were noted in both amantadine and placebo 
groups (70% vs. 56% improving at least 3 points on Day 60 Observer NPI-A; p=0.11). 
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Conclusion: Amantadine 100 mg twice daily in this population with chronic TBI appears 
to be beneficial in decreasing aggression from the perspective of the individual with TBI.  
No beneficial impact on anger was found. 
Trial Registration: clinicaltrials.gov Identifier: NCT00779324; 
http://www.clinicaltrials.gov/ct2/show/NCT00779324?term=irritability&rank=6 
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INTRODUCTION 
Anger and aggression are among the more common manifestations of affective and 
behavioral dysregulation observed following traumatic brain injury (TBI).1-3 Aggression 
has been observed in approximately 25-73% of individuals with chronic TBI.1,2,4 
Compared to uninjured age, gender, and education-matched peers, after moderate-severe 
TBI excessive anger occurs in 39% (compared to 20%) and verbal aggression in 41% 
(compared to 18%).5  While in an angry or aggressive state, interpersonal communication 
is often non-adaptive and information processing inefficient resulting in poorer 
rehabilitation outcomes, exclusion from rehabilitation services due to safety concerns, 
social isolation, interpersonal and relationship stresses and losses, caregiver burden,  
criminal behavior, inability to live at home, and employment challenges. 2 
Despite the substantial impact, systematic reviews have revealed minimal 
evidence for efficacious pharmacologic treatment of aggression and anger after TBI.6,7 
Arciniegas et al.3 suggested the agents most likely to be effective are those that enhance 
the function of neural circuitry facilitating top-down regulation of behavior, assuming 
that these areas are relatively preserved post-TBI. However, when prefrontal areas are not 
intact, targeting the limbic catecholaminergic functions directly may be a logical option. 
For example, amantadine is a pleotropic agent with indirect pre-synaptic and direct post-
synaptic dopaminergic effects, N-methyl-D-aspartate channel antagonism, and 
serotonergic effects that may influence top-down regulation through enhanced cognitive 
appraisal and behavioral disinhibition.   
Preliminary evidence suggest amantadine may reduce TBI related aggression.  
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Hammond et al.8 enrolled 76 individuals with chronic TBI (> 6 months post-injury) and 
associated irritability into a single-site, randomized, controlled trial of amantadine 100mg 
twice daily versus placebo for 28 days. For those with aggression at baseline (n=68), the 
amantadine group experienced significantly greater improvement than the placebo group 
on observer-rated Neuropsychiatric Inventory Aggression (NPI-A) using the item rated as 
most problematic. In the amantadine group, NPI-A Most Problematic mean change was -
4.56 compared to -2.46 in the placebo group (p=0.046). This study assessed only an 
observer‘s perspective (an observer was someone close enough to the person with brain 
injury to have regular interactions and witness behaviors). Observer distress regarding 
aggression did not differ significantly between the two arms. Some observers did not 
have considerable distress at baseline.  
The study was replicated with a larger, multi-site sample using both observer and 
participant perspectives of irritability, aggression, and anger. For the irritability outcome, 
Hammond et al.9 found observer ratings between the two groups were not statistically 
significantly different at Day 28 or 60; however, the majority in both groups had 
improved at both assessments compared to baseline. While the result of this study of 
amantadine 100 mg every morning and noon to reduce irritability was not positive from 
the Observer perspective, there were indications of improvement in irritability at day 60 
from the perspective of persons with TBI and clinicians that may warrant further 
investigation.  
The present study aims to study the effect of amantadine on aggression and anger 
in the cohort of participants from the Hammond, et al9 multi-site, prospective, double-
blind, randomized, placebo-controlled trial who had moderate-severe aggression at 
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baseline. We hypothesized that, compared to placebo, amantadine (100 mg every 
morning and noon) administered to individuals with aggression (NPI-A Most Problematic 
> 6) following TBI (at least 6 months post-injury), would result in reduced aggression 
(frequency, severity, and distress) at days 28 and 60 as measured by an observer and the 
participant with TBI. For purposes of this study we defined aggression as a NPI-A Most 
Problematic score of at least 6. We also hypothesized that amantadine would result in 
reduced anger at days 28 and 60 as measured by an observer and the participant with 
TBI. We measured anger using the State Trait Anger Expression Inventory (STAXI-2). 
Secondarily we studied the effects of amantadine on the entire cohort to include those 
with mild or no aggression at baseline (results available in supplemental digital content).  
 
METHODS 
Setting 
Study sites were: Carolinas Rehabilitation in Charlotte, North Carolina (lead site), 
Indiana University/ Rehabilitation Hospital of Indiana (Indianapolis, IN), Kessler 
Institute of Rehabilitation (West Orange, New Jersey); Spaulding Rehabilitation Hospital 
(Boston, MA); TIRR Memorial Hermann (Houston, TX); The Ohio State University 
(Columbus, OH); University of Washington (Seattle, WA). 
 
Study Oversight 
Each site received Institutional Review Board approval. The study was registered on 
www.clinicaltrials.org (#NCT00779324). Participants and observers gave their informed 
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consent. A data coordinating center managed the concealed treatment allocation, data 
storage, and data monitoring, and upon study closure, transferred the data to the 
statistician. Independent oversight was provided though an external Data and Safety 
Monitoring Board 
 
Participants 
Recruitment was through referrals, physician letters, newsletters, and support 
groups. Eligibility criteria, including presence of TBI, are summarized in Table 1. Most 
participants lived in the community although this was not required. Study participants 
were expected to have no anticipated major life events or changes, surgeries, new 
therapies or changes in medications during the course of the study. We did not attempt to 
control for or compare groups on environment, medications, therapy involvement, 
stressors, and other such factors that may impact behavior or potentiate treatment effects 
since these factors are highly variable. For example, both rehabilitation and psychological 
therapies may vary considerably in approach and quality among providers and hence 
there is no accepted method to quantify the impact of these types of therapy.  Rather we 
relied on random assignment to control for this and other extraneous variables between 
groups. Measures administered to participants as well as an observer. An observer was 
defined as someone close enough to the person with brain injury to have sufficient 
interactions to witness the participant’s behaviors through out the study. 
For the present study of aggression and anger, we a priori planned to analyze two 
samples: 1) The subset of individuals with moderate or severe aggression (those with 
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NPI-A Most Problematic <6 were excluded); and 2) The entire sample from the trial for 
treatment of irritability which included participants with no or mild aggression at 
baseline.  The results of both analyses are included in this manuscript with an emphasis 
on the analyses of the subset with moderate or severe aggression. The original sample 
size of 168 was based on the power needed to replicate the study of the effect of 
amantadine on the primary outcome (irritability) and allow for 8% attrition.9,10 
 
Procedures 
Data (demographics, medical history, and injury data) were collected and verified 
through interview and record review. Measures of participant behavior were administered 
to the participant and the participant’s observer. After confirmation of eligibility and 
baseline assessment, participants were randomly allocated to take amantadine (100 mg 
every morning and noon) or placebo equivalent. In cases of presumed drug intolerance, 
the dose was reduced or terminated per pre-specified protocol. Participants and observers 
completed the assessment measures at baseline, and treatment day 28 and day 60. 
Definition of medication compliance was pre-specified as taking at least 80% of the study 
medication.  
 
Randomization and Masking 
Computer-generated block randomization was performed and concealed group allocation 
occurred through the study web page managed by the data coordinating center. After the 
site coordinators entered the participant’s eligibility data and eligibility confirmed, the 
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data coordinating center assigned a study number which indicated which study drug kit to 
dispense. Randomization was stratified for depression (< 13 vs. > 13 on the Beck 
Depression Inventory – II) for the trial of amantadine for reduction of irritability. This 
was done to ensure equal distribution of depression in the amantadine and placebo groups 
because depression is common after TBI and irritability can be associated with 
depression. The compounding pharmacist and data coordinating center had access to 
group assignment, while all study personnel, participants, and observers were blinded to 
group allocation. 
 
Measures 
The study outcome measures were chosen based on the measures’ ability to 
operationalize the concepts of aggression and anger, and the wide use of these measures 
in both TBI and dementia literature. The NPI-A has demonstrated sensitivity to changes 
in aggression in prior medication trials such as Hammond, et al. single site amantadine 
study.8  
NPI – Agitation/Aggression (NPI – A) Most Problematic: The NPI assesses 12 behavioral 
domains,11 including aggression. For this study, only the Irritability domain (administered 
for eligibility) and Agitation/Aggression domain were administered. The NPI-A domain 
asks if over the preceding month the individual got upset, resisted activities, shouted, 
cursed angrily, slammed doors, kicked furniture, threw things, hurt or hit others, or was 
stubborn, uncooperative or hard to handle. Typical administration has the rater determine 
the frequency (1-4) and severity (1-3) of the most aberrant of these behavior(s) with the 
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possibility that this rating will include several relevant items. This is a complex task 
made more difficult with the memory and executive function deficits accompanying TBI. 
Thus, we had the raters indicate which of these behaviors were present and which one 
item was the most problematic. We then had them rate the frequency and severity of that 
one item, referred to as Most Problematic. The domain score is obtained by multiplying 
the severity and frequency ratings.11 Consistent with the design of the measure, the NPI 
was rated by the observer. A version was also developed and used to record participant 
report. 
NPI-A Distress: NPI-Distress measures the rater’s distress related to the behavior using a 
6-point scale.12 Observers rated the NPI-A Distress about the participant’s aggressive 
behavior, participants rated their distress about their own behavior. 
State Trait Anger Expression Inventory (STAXI-2): The STAXI-2,13 captures the 
experience and the expression of anger through 57 questions about intensity and 
frequency using a 4-point Likert scale. STAXI-2 has internal consistency (α coefficient 
0.86) 13 and has been used in TBI studies.14,15 It is comprised of 3 parts: Part 1 (State 
Anger), Part 2 (Trait Anger), and Part 3 (Anger Expression). The STAXI-2 was 
administered as designed, to the person expressing the anger (participants). With 
permission from the measure’s author, we modified the tool to capture an external view, 
and administered to observers.  
Other measures: To characterize the sample’s level of functioning, the Glasgow Outcome 
Scale-Extended (GOS-E),16 was collected at baseline as was the Beck Depression 
Inventory-II.17  which was used to stratify the sample on depression during 
randomization. 
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Statistical Methods 
Analyses were performed using SAS® 9.4 and were conducted using the intention-to-
treat principle. A two-tailed p-value <0.05 was considered statistically significant. The 
treatment groups were compared on baseline characteristics. For ordinal variables, the 
normal approximation for the Wilcoxon rank sum test was used. For categorical 
variables, Chi-square tests or Fisher’s exact tests were used.  
Pre-specified analyses for the subsample of persons with observer reported 
moderate to severe aggression (NPI-A ≥ 6) included: 1) Comparison of the change in 
NPI-A and STAXI-2 scores from baseline to Day 28 and Baseline to Day 60; and 2) 
Comparison of the percentages of participants who decreased at least 3 points in the NPI-
A Most Problematic (a priori definition of meaningful change in aggression). Change in 
NPI-A Most Problematic (frequency x severity), NPI-A Distress, and STAXI-2 scores 
(State, Trait, and Anger) from baseline to Day 28 and baseline to Day 60 were compared 
between the two groups using a Wilcoxon rank sum (Mann-Whitney) test for ordinal 
data. For analysis of NPI-A Distress, those with no or mild Observer distress (NPI-A 
Distress scores of 0-2) at baseline were excluded as pre-specified in the protocol. The 
percentages of participants with decrease in NPI-A of at least 3 points from baseline to 28 
days and baseline to Day 60 was compared between the two groups using chi-square or 
Fisher’s exact test.  P-values for the Wilcoxon rank sum tests were adjusted for multiple 
comparisons within the domain of respondent, follow up interval, and instrument (e.g., 
NPI-A, STAXI) utilizing the Holm’s sequential Bonferroni method.18 As planned, all 
analyses were repeated on the entire cohort from the irritability trial.  
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RESULTS 
Participants 
To derive the original cohort, 324 individuals were screened and 168 were enrolled and 
randomized (86 placebo and 82 amantadine) as previously published.9 11 (6.6%) of the 
participants (4 placebo and 7 amantadine) did not complete the study. Compliance (>80% 
prescribed study drug consumed per pill count) was high with 88.5% compliance in 
amantadine group and 86.9% in placebo group.  
 Of the cohort of 168 irritability study participants, 118 showed moderate or severe 
aggression at baseline assessment as indicated by observer reported moderate to severe 
aggression (NPI-A ≥ 6). Of these, 57 were randomized to the placebo control group and 
61 were randomized to amantadine. Figure 1 depicts the flow diagram for the aggression 
subset. Table 2 summarizes the baseline characteristics of the amantadine and placebo 
groups for the subset with moderate-severe aggression and the entire original group. For 
both study samples, the groups were well-matched with respect to baseline factors. The 
prevalences of specific aggressive behaviors on the NPI-A are summarized in Figure 2 
for both the entire cohort and the moderate-severe aggression cohort. Although the 
frequency and severity ratings differed, the prevalences for each behavior were similar.  
[Figure 1 about here] 
[Table 2 about here]  
[Figure 2 about here] 
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Moderate or Severe Aggression Sample 
The aggression cohort group comparisons of change from baseline to Day 28 and 
baseline to Day 60 for the ordinal outcome measures are summarized in Table 3. For 
illustrative purposes, the mean NPI-A Most Problematic scores at each assessment period 
for Participants and Observers are depicted in Figure 3. 
Day 28: Group comparison of change in the measures from baseline to Day 28 were not 
significant on the NPI-A or STAXI-2 Observer or Participate rated ordinal measures nor 
were the percentage who improved at least 3 points on Observer NPI-A [58.3% in 
amantadine vs. 53.7% in placebo (p=0.6189)] or at least 3 points on Participant NPI-A 
Most Problematic [40.0% in amantadine vs. 41.8% in placebo (p=0.8429)].  
Day 60: Change in Participant-rated NPI-A Most Problematic was statistically significant 
(adjusted p=0.0118) in favor of amantadine. Similarly, change in Participant Distress was 
significantly improved (adjusted p=0.0118) in the amantadine group compared to placebo 
group for those with baseline Observer Distress score >2. There were no group 
differences on the NPI-A Observer or Observer or Participant STAXI-2 ordinal 
outcomes. There were no significant differences for the percentage who improved at least 
3 points on Observer NPI-A [70.2% in amantadine vs. 55.6% in placebo (p=0.1107); 
(i.e.: 15% more people in the amantadine group were responders)] or at least 3 points on 
Participant NPI-A Most Problematic [47.4% in amantadine vs. 38.2% in placebo 
(p=0.3260); (i.e.: 7% more people in the amantadine group were responders)].  
[Table 3 about here] 
[Figure 3 about here] 
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Entire Sample 
On baseline Observer ratings, 29.2% had mild aggression (NPI-A score of 1-5) and 0.6% 
had no aggression; participant baseline ratings included 44.1% with mild aggression and 
7.7% with no aggression. Baseline observer distress was 0 for 1.2% and 1-2 for 9.5%; 
baseline participant distress was 0 in 15.5% and 1-2 in 25.6% cases. The group 
comparisons for change from baseline to Day 28 and baseline to Day 60 for the ordinal 
outcome measures are summarized in supplemental digital content Table 4 and Figure 4. 
 
Adverse Events 
Amantadine was well tolerated among study participants with no significant between 
groups differences on withdrawals/lost or adverse events (using Fisher’s Exact Test). 
Adverse events are summarized elsewhere.9  
 
DISCUSSION 
This is the largest study of aggression and anger treatment among those with chronic TBI 
(> 6 months post-injury). While both amantadine and placebo groups showed 
improvement on the measures, several analyses of Participant ratings demonstrated 
superior improvements in the magnitude and frequency of change in aggression for the 
amantadine group, while the changes in anger ratings were not superior. Taken together 
these findings suggest that the hypothesis that amantadine may be an effective 
intervention for reducing post-TBI aggression frequency severity and distress (Day-60 
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NPI-A Most Problematic and NPI-A Distress) from the perspective of the person with 
brain injury is accepted, but not from the observer perspective. The hypothesis that anger 
is reduced by amantadine is not accepted. 
As was seen in the earlier (primary) study of the effect of amantadine on post-TBI 
irritability, (Hammond et al., 2015) substantial improvement was seen for participants in 
the control condition for virtually all outcome measures. The occurrence of such frequent 
improvement in the control group may have complicated our ability to detect a treatment 
effect for amantadine. In the earlier report of analyses of irritability data,9 we discussed 
possible factors that may have been contributed to this placebo effect in greater detail, 
including behavioral monitoring19 and nonspecific factors, such as, therapeutic alliance 
and positive expectations.20,21 Study participants were required to have significant 
irritability but not aggression.  Consequently, it seems unlikely that regression to the 
mean can explain the positive effect on aggression for the control group.  Since all 
participants were more than 6 months post-injury, spontaneous recovery also seems 
unlikely as a cause of the improvement for controls.  Clinical trial designs such as a 
Sequential Parallel Comparison Design and placebo run-in will need to be considered 
given the large placebo response in the control group.22 The role of the placebo especially 
when manipulating dopaminergic therapy and seeking a chronic behavioral target will 
also need to be considered.23  
The findings may have revealed clinical significance without reaching statistical 
significance. The comparisons of the “proportion of clinically meaningful NPI-A 
responders” all favored amantadine over placebo with up to 10-15% more responders. 
Although many of these comparisons did not reach statistical significance, it is worth 
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considering if this might have clinical significance. Although the outcome measures were 
chosen for their prior use and sensitivity in brain injury and dementia populations, it is 
possible that the measures lack the sensitivity needed to detect and differentiate 
meaningful changes for this intervention. 
There are several potential reasons why between group difference in participant 
ratings were significant while observer ratings were not. It is worth noting that the 
participant NPI-A ratings at baseline were lower than the observer ratings for both the 
entire sample and the aggressive subset, as depicted in Figure 1 and 2. This may be, in 
part, due to impaired self-awareness and participant awareness of moderate-severe 
aggression not needed for study inclusion. Having rated themselves lower at baseline, this 
would be expected to impact the proportion who could possibly improve by at least three 
points. That is, many participants may have started at a level that left little or no room to 
reach our predefined level of clinically meaningful difference. The amount and nature of 
burden would have varied across observers. Additionally, observer burden may take 
longer observation period or more change to differentiate treatment from placebo on 
observer ratings. 
The evidence base for pharmacologic treatment of aggression for those with post-
acute TBI remains limited. The current findings make a contribution to this evidence by 
providing modest, but encouraging evidence that amantadine may provide some benefit 
in treating aggression persons with TBI. As reported by Hammond et al. (2015), the side 
effect profile of amantadine in this trial was favorable with no consequential difference in 
side effects between the amantadine and placebo groups. However, prescribers should be 
aware that individuals with uncontrolled seizure disorder, psychosis, and renal 
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impairment were not included in this study, and amantadine, at least at the tested dosing, 
should not be used in the presence of renal failure.24 Given the favorable safety findings 
and modest evidence of reduction of aggressive, clinicians can consider amantadine as a 
possible treatment for post-TBI aggression. However, given limited evidence to this 
point, treated patients should be followed closely to ensure that any response to 
intervention is favorable. 
A few limitations should be considered. First, subjective measures were used in 
order to capture anger and aggression during daily living given the impracticality of 
outcome examiners directly observing behavioral episodes in which aggression might 
occur in an outpatient setting over a prolonged time period. Second, the observers were 
not required to have a caregiving role with the participant or bear the brunt of the 
participant’s behaviors. Third, no particular level of observer or participant distress was 
required for enrollment. Fourth, this study may not have been adequately powered to 
detect a possible beneficial impact of anger. Lastly, the study centered on chronic 
aggression and may not generalize to aggressive behaviors or anger during the acute 
period after TBI.  
 
CONCLUSION 
Amantadine 100 mg twice daily in this population with chronic TBI (> 6 months post-
injury) appears to be beneficial in decreasing aggression, particularly from the 
perspective of the individual with brain injury. Further studies may be needed to detect 
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effect of amantadine on anger using larger sample size, different measures, and study 
design that better accounts for placebo effects.  
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Figure 1: CONSORT diagram showing study flow
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Figure 2: Prevalences of Baseline Aggressive Behaviors  
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Figure 3: Mean Observer and Participant ratings for NPI – Aggression Most 
Problematic at Baseline, Day 28, and Day 60 for the Moderate-Severe Aggression 
Subset 
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Figure 4 Supplemental Digital Content: Mean Observer and Participant ratings for 
NPI – Aggression Most Problematic at Baseline, Day 28, and Day 60 for the Entire 
Sample 
 
Table 1: Eligibility Criteria 
 
INCLUSION CRITERIA: 
Moderate, severe, or complicated mild traumatic closed head injury (defined as 
impaired brain function resulting from externally inflicted trauma without penetrating 
injury) at least 6 months prior to enrollment with evidence from medical record, 
clinician report, and/or detailed history to meet one of the following criteria:  
-post-resuscitation Glasgow Coma Scale (GCS) score 13 or lower;  
-if patient intubated and off paralytics, post-resuscitation GCS Motor < 6;  
-loss of consciousness attributable to the brain injury;  
-disorientation attributable to the brain injury and persisting ≥ 24 hours; 
-post-traumatic amnesia lasting > 24 hours;  
-neuro-imaging study with TBI-related findings such as contusion, hematoma, 
hemorrhage, diffuse axonal injury, shear injury, and/ or depressed skull fracture;  
-other evidence of TBI-related focal neurological findings  
Intoxication, sedation, intubation, or paralytics not cause of impaired consciousness. 
Irritability that is either new or worse than level of irritability before the TBI 
Age at time of enrollment: 16 to 75 years  
Voluntary informed consent and authorization of participant and  observer 
Subject and observer willing to comply with the protocol 
Observer-rated NPI Irritability Domain score 6 or greater (moderate-to-severe irritability) 
Medically and neurologically stable during the month prior to enrollment 
No change in medications planned during study or during month prior to enrollment 
No surgeries planned during study 
Any rehabilitation, psychological, and behavioral therapies commenced at least one 
month prior to enrollment and none planned to start during study 
Vision, hearing, speech, motor function, and comprehension sufficient to complete interviews 
Observer (e.g.: family member, close friend, employer) with whom subject interacts 
sufficiently to observe occurrences of irritability.  
EXCLUSION CRITERIA: 
Previous participation in the single-site amantadine irritability study 
Ingestion of amantadine hydrochloride during the month prior to enrollment 
Potential subject without a reliable observer 
Penetrating head injury as defined by head injury due to gunshot, projectile or foreign object 
Injury < 6 months prior to enrollment 
Inability to interact sufficiently for communication 
Clinical signs of active infection 
Diagnosis of seizure in the month prior to enrollment 
Creatinine clearance <60 mL/min (calculated using serum creatinine) 
Pregnancy, lactating female; sexually active female without use of birth control 
Concurrent use of neuroleptic agents   
Concurrent active enrollment and participation in a different treatment study 
History of schizophrenia or psychosis 
Active concern of potential harm to self or others 
Diagnosis of progressive or additional neurologic disease that affects brain function 
Previous allergy or adverse reaction to amantadine hydrochloride 
 
Table 2: Baseline Participant Characteristics by Treatment Group for Entire Sample and Subset with Moderate or Severe 
Aggression: 
Variable Category Placebo 
(n=86) 
Amantadine 
(n=82) 
p-value Placebo 
(n=57) 
Amantadine 
(n=61) 
p-value 
  % %  % %  
  Entire Sample Moderate or Severe Aggression (NPI-A >6) 
Gender Male 74.4% 80.5% 0.3473 75.4% 83.6% 0.2707 
Race Caucasian 87.2% 89.0% 0.9359 84.2% 90.2% 0.6478 
Black 5.8% 6.1%  8.8% 4.9%  
Other 7.0% 4.9%  7.0% 4.9%  
Hispanic Yes 9.3% 3.7% 0.1394 8.8% 4.9% 0.4802 
Education Less than HS 16.3% 6.1% 0.3472 19.3% 3.3% 0.1805 
HS diploma 30.2% 37.8%  29.8% 42.6%  
Some college 34.9% 34.1%  38.6% 34.4%  
Bachelors or 
toward masters 
11.6% 14.6%  7.0% 13.1%  
Masters and above 7.0% 7.3%  5.3% 6.6%  
Cause of injury Vehicular 61.6% 69.5% 0.5513 57.9% 73.8% 0.2069 
Fall 18.6% 13.4%  17.5% 11.5%  
Assault 10.5% 6.1%  14.0% 6.6%  
Sport-related 3.5% 1.2%  5.3% 0%  
Pedestrian 3.5% 7.3%  3.5% 4.9%  
Other 2.3% 2.4%  1.8% 3.3%  
Loss of 
consciousness 
duration 
<1 hour 27.9% 23.1% 0.6845 33.3% 20.3% 0.2867 
≥1 hour but <24 
hours 
15.1% 12.8%  15.8% 15.3%  
1-6 days 16.3% 24.4%  15.8% 27.1%  
7-13 days 8.1% 6.4%  7.0% 8.5%  
14-20 days 9.3% 12.8%  8.8% 10.2%  
21-29 days 10.5% 9.0%  7.0% 6.8%  
30-59 days 9.3% 6.4%  10.5% 8.5%  
≥60 days 3.5% 5.1%  1.8% 3.4%  
<24 hours 9.6% 11.5% 0.9685 10.9% 10.3% 0.3444 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Post-traumatic 
amnesia 
duration 
1-6 days 22.9% 11.5%  27.3% 12.1%  
7-13 days 4.8% 10.3%  5.5% 10.3%  
14-20 days 9.6% 14.1%  10.9% 17.2%  
21-29 days 12.0% 10.3%  14.5% 10.3%  
30-59 days 15.7% 23.1%  10.9% 20.7%  
≥60 days 25.3% 19.2%  20.0% 19.0%  
History >1 TBI Yes 18.6% 13.4% 0.3599 24.6% 11.5% 0.0633 
Total Glasgow 
Coma Scale 
score  
3-8 30.8% 22.5% 0.4672 30.8% 18.5% 0.2109 
9-12 1.3% 4.2%  0% 1.9%  
13-15 25.6% 23.9%  28.8% 24.1%  
Chemically 
paralyzed, 
chemically induced 
coma, or intubated 
42.3% 49.3%  40.4% 55.6%  
  Median (Q1, Q3) Median ( Q1, Q3)  Median ( Q1, Q3) Median ( Q1, Q3)  
Age at enrollment 38.1 (26.2, 47.2) 38.6 (30.7, 52.2) 0.2814 35.5 (26.2, 46.0) 37.6 (30.9, 50.4) 0.3830 
Age at injury 30.5 (22.0, 40.9) 32.3 (22.8, 42.2) 0.3803 28.3 (21.4, 40.5) 30.0 (23.9, 39.6) 0.3771 
Observer NPI irritability Most 
Problematic 
8.0 (6.0, 9.0) 8.0 (6.0, 12.0) 0.7859 9.0 (8.0, 9.0) 9.0 (8.0, 12.0) 0.3609 
Participant NPI irritability Most 
Problematic 
6.0 (3.0, 8.0) 6.0 (3.0, 8.0) 0.8593 6.0 (4.0, 8.0) 6.0 (4.0, 9.0) 0.9016 
Observer NPI irritability Most 
Problematic Distress 
4.0 (3.0, 4.0) 4.0 (3.0, 4.0) 0.5421 4.0 (3.0, 5.0) 4.0 (3.0, 5.0) 0.6936 
Participant NPI irritability Most 
Problematic Distress 
3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.9427 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 0.5415 
Observer NPI aggression Most 
Problematic 
6.0 (4.0, 8.0) 6.0 (4.0, 8.0) 0.7593 8.0 (6.0, 9.0) 8.0 (6.0, 9.0) 0.5715 
Participant NPI aggression Most 
Problematic 
4.0 (2.0, 8.0) 6.0 (2.0, 8.0) 0.5606 6.0 (3.0, 8.0) 6.0 (3.0, 8.0) 0.8491 
Observer NPI aggression Most 
Problematic Distress 
4.0 (3.0, 5.0) 4.0 (3.0, 4.0) 0.4941 4.0 (3.0, 5.0) 4.0 (3.0, 4.0) 0.0796 
Participant NPI aggression Most 
Problematic Distress 
3.0 (1.0, 4.0) 3.0 (1.0, 4.0) 0.5232 3.0 (2.0, 4.0) 3.0 (1.0, 4.0) 0.2289 
Beck’s Depression Inventory-II Total 18.5 (11.0, 30.0) 19.0 (10.0, 28.0) 0.6613 19.0 (12.0, 30.0) 18.0 (9.0, 27.0) 0.2489 
Glasgow Coma Scale-Extended 5.0 (4.0, 6.0) 5.0 (5.0, 6.0) 0.0492* 5.0 (4.0, 6.0) 6.0 (5.0, 6.0) 0.0745 
*=statistically significant 
 Q1 = 25th percentile, Q3 = 75th percentile
  
Table 3: Group Comparison of Change in Observer and Participant Ratings of Aggression and Anger from 
Baseline to Days 28 and 60 for Subset with Moderate or Severe Aggression (NPI-A >6): Amantadine N = 61) 
versus Placebo (N = 57) 
Variable Group Mean Change 
(SD) 
Median Change 
(Q1, Q3) 
p-value Adjusted 
p-value 
Baseline to Day 28     
NPI-A Most Problematic  
Observer 
Placebo -2.70 (3.42) -3.0 (-5.0, 0.0) 0.3618 0.7236 
Amantadine -3.33 (3.13) -3.0 (-6.0, 0.0) 
NPI-A Most Problematic 
Participant 
Placebo -3.38 (3.61) -5.0 (-6.0, 0.0) 0.4741 0.4741 
Amantadine -4.15 (3.38) -4.0 (-6.0, -2.0) 
NPI-A Distress Observer for 
those with distress >2 
Placebo -1.15 (1.66) -1.0 (-2.0, 0.0) 0.9374 0.9374 
Amantadine -1.09 (1.28) -1.0 (-2.0, 0.0) 
NPI-A Distress Participant 
for those with distress >2 
Placebo -1.18 (1.57) -1.0 (-3.0, 0.0) 0.1111 0.2222 
Amantadine -1.97 (1.97) -2.0 (-4.0, 0.0) 
STAXI State Anger Observer Placebo -2.88 (11.74) 0.0 (-9.0, 3.0) 0.5937 1.0000 
Amantadine -2.73 (12.56) -1.0 (-9.0, 0.0) 
STAXI State Anger 
Participant 
Placebo -2.86 (5.99) 0.0 (-4.0, 0.0) 0.3102 0.8080 
Amantadine -1.95 (7.91) 0.0 (-4.0, 0.0) 
STAXI Trait Anger Observer Placebo -9.62 (13.12) -7.0 (-17.0, 0.0) 0.5604 1.0000 
Amantadine -8.10 (13.06) -8.0 (-18.0, 0.0) 
STAXI Trait Anger 
Participant 
Placebo -9.08 (12.41) -8.0 (-14.0, 0.0) 0.3940 0.8080 
Amantadine -11.51 (12.36) -10.0 (-18.0, -2.0) 
STAXI Anger Expression 
Observer 
Placebo -6.73 (11.20) -4.0 (-11.0, 0.0) 0.1546 0.4638 
Amantadine -8.07 (9.48) -6.0 (-15.0, -2.0) 
STAXI Anger Expression 
Participant 
Placebo -5.78 (9.53) -4.0 (-12.0, 0.0) 0.2693 0.8080 
Amantadine -9.76 (14.08) -8.0 (-20.0, 0.0) 
Baseline to Day 60    
NPI-A Most Problematic  
Observer 
Placebo -3.04 (4.09) -3.5 (-6.0, 0.0) 0.2062 0.4123 
Amantadine -3.91 (3.15) -4.0 (-6.0, -2.0) 
NPI-A Most Problematic 
Participant 
Placebo -2.89 (3.31) -3.0 (-6.0, 0.0) 0.0059* 0.0118* 
Amantadine -5.27 (3.52) -6.0 (-8.0, -2.0) 
NPI-A Distress Observer for 
those with distress >2 
Placebo -1.26 (1.68) -1.0 (-2.0, 0.0) 0.2623 0.4123 
Amantadine -1.54 (1.34) -2.0 (-2.0, -1.0) 
NPI-A Distress Participant 
for those with distress >2 
Placebo -1.44 (1.52) -1.0 (-3.0, 0.0) 0.0086* 0.0118* 
Amantadine -2.56 (1.55) -3.0 (-4.0, -1.0) 
STAXI State Anger Observer Placebo -0.68 (14.07) 0.0 (-4.0, 4.0) 0.0551 0.1653 
Amantadine -4.95 (11.23) -2.0 (-10.0, 0.0) 
STAXI State Anger 
Participant 
Placebo -2.59 (9.11) 0.0 (-6.0, 0.0) 0.7664 1.0000 
Amantadine -3.24 (6.19) -2.0 (-6.0, 0.0) 
STAXI Trait Anger Observer Placebo -10.53 (15.05) -6.0 (-22.0, 0.0) 0.2574 0.5148 
Amantadine -12.91 (13.14) -14.0 (-22.0, -2.0) 
STAXI Trait Anger 
Participant 
Placebo -11.68 (10.32) -12.0 (-18.0, -6.0) 0.6107 1.0000 
Amantadine -14.16 (12.31) -12.0 (-22.0, -4.0) 
STAXI Anger Expression 
Observer 
Placebo -10.08 (13.13) -8.0 (-18.0, 0.0) 0.3311 0.5148 
Amantadine -10.88 (10.89) -8.0 (-18.0, -2.0) 
STAXI Anger Expression 
Participant 
Placebo -6.92 (9.84) -6.0 (-12.0, 0.0) 0.0195* 0.0586 
Amantadine -13.62 (12.96) -12.0 (-24.0, -2.0) 
*= statistically significant 
Q1 = 25th percentile, Q3 = 75th percentile 
 
  
Table 4 Supplemental Digital Content: Group Comparison of Change in Observer and Participant Ratings of 
Aggression and Anger from Baseline to Days 28 and 60 for Entire Sample: Amantadine N = 82) versus 
Placebo (N = 86) 
 
Variable Group Mean Change 
(SD) 
Median Change 
(Q1, Q3) 
p-value Adjusted 
p-value 
Baseline to Day 28      
NPI-A Most Problematic  
Observer 
Placebo -1.28 (3.73) -1.0 (-4.0, 2.0) 0.0467* 0.0934 
Amantadine -2.38 (3.51) -2.0 (-5.0, 0.0) 
NPI-A Most Problematic Participant Placebo -1.57 (3.33) -1.0 (-4.0, 0.0) 0.2234 0.4467 
Amantadine -2.26 (3.44) -2.0 (-4.0, 0.0)  
NPI-A Distress Observer for those with 
distress >2 
Placebo -0.96 (1.60) -1.0 (-2.0, 0.0) 0.1800 0.1800 
Amantadine -1.24 (1.36) -1.0 (-2.0, 0.0) 
NPI-A Distress Participant for those 
with distress >2 
Placebo -1.38 (1.75) -1.0 (-3.0, 0.0) 0.2321 0.4467 
Amantadine -1.86 (1.86) -1.5 (-3.0, 0.0) 
STAXI State Anger Observer Placebo -2.28 (11.86) 0.0 (-8.0, 2.0) 0.9624 1.0000 
Amantadine -1.18 (12.94) 0.0 (-8.0, 2.0) 
STAXI State Anger Participant Placebo -1.98 (8.80) 0.0 (-4.0, 0.0) 0.1898 0.2784 
Amantadine -1.09 (7.01) 0.0 (-4.0, 0.0) 
STAXI Trait Anger Observer Placebo -8.15 (13.31) -6.0 (-16.0, 0.0) 0.3561 1.0000 
Amantadine -6.60 (12.85) -3.0 (-15.0, 0.0) 
STAXI Trait Anger Participant Placebo -7.01 (10.92) -4.0 (-12.0, 0.0) 0.1025 0.2784 
Amantadine -10.05 (11.48) -8.0 (-16.0, 0.0) 
STAXI Anger Expression Observer Placebo -6.68 (11.81) -4.0 (-12.0, 2.0) 0.4628 1.0000 
Amantadine -6.78 (10.71) -6.0 (-13.0, 0.0) 
STAXI Anger Expression Participant Placebo -4.59 (9.00) -4.0 (-10.0, 2.0) 0.0928 0.2784 
Amantadine -7.82 (11.61) -4.0 (-16.0, 0.0) 
Baseline to Day 60     
NPI-A Most Problematic  
Observer 
Placebo -1.61 (4.31) -2.0 (-4.0, 0.0) 0.0245* 0.0491* 
Amantadine -3.01 (3.41) -3.0 (-5.0, 0.0) 
NPI-A Most Problematic Participant Placebo -1.61 (2.82) -1.0 (-3.0, 0.0) 0.1592 0.1592 
Amantadine -2.63 (3.95) -2.0 (-6.0, 0.0) 
NPI-A Distress Observer for those with 
distress >2 
Placebo -1.19 (1.66) -1.0 (-2.0, 0.0) 0.0601 0.0601 
Amantadine -1.66 (1.36) -2.0 (-3.0, -1.0) 
NPI-A Distress Participant for those 
with distress >2 
Placebo -1.60 (1.75) -1.0 (-3.0, 0.0) 0.0659 0.1318 
Amantadine -2.25 (1.53) -2.0 (-3.0, -1.0) 
STAXI State Anger Observer Placebo -0.84 (12.88) 0.0 (-4.0, 4.0) 0.0359* 0.1078 
Amantadine -4.05 (12.10) -2.0 (-10.0, 0.0) 
STAXI State Anger Participant Placebo -1.66 (9.75) 0.0 (-4.0, 0.0) 0.7125 0.8338 
Amantadine -1.52 (7.00) 0.0 (-4.0, 0.0) 
STAXI Trait Anger Observer Placebo -9.73 (14.61) -8.0 (-22.0, 0.0) 0.3968 0.6920 
Amantadine -11.41 (13.37) -12.0 (-22.0, 0.0) 
STAXI Trait Anger Participant Placebo -8.93 (9.95) -8.0 (-14.0, -2.0) 0.4169 0.8338 
Amantadine -10.69 (12.23) -10.0 (-20.0, -2.0) 
STAXI Anger Expression Observer Placebo -9.69 (13.21) -6.0 (-18.0, 0.0) 0.3460 0.6920 
Amantadine -10.16 (10.95) -8.0 (-18.0, -2.0) 
STAXI Anger Expression Participant Placebo -6.00 (10.23) -5.0 (-10.0, 2.0) 0.0707 0.2120 
Amantadine -9.39 (11.65) -8.0 (-16.0, 0.0) 
*= statistically significant 
Q1 = 25th percentile, Q3 = 75th percentile 




